Unseen threat: how subclinical atherosclerosis increases mortality risk in patients with type 1 diabetes
Authors' conclusion
Subclinical atherosclerosis is independently associated with increased overall mortality and MACE in patients with type 1 diabetes. Identifying clinical predictors can improve risk stratification and personalised therapeutic strategies to prevent MACEs in this high-risk population.
Study context
- Population
- T1D patients without overt cardiovascular disease (CVD), aged ≥18 with diabetes ≥10 years or aged ≥40 with diabetes ≥5 years, Diabetes Unit, Hospital of Girona Doctor Josep Trueta, 2015–2023
- Participants
- 507 patients
- Exposure
- Subclinical atherosclerosis vs none
- Subclinical atherosclerosisn = 218
- Outcome
- Prevalence of subclinical atherosclerosis
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Subclinical atherosclerosis prevalence
Subclinical atherosclerosis
43%
218
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value | |
|---|---|---|---|
| MACE · mean follow-up 70.64 ± 27.08 months | HR 25.1 (95% CI 5.81–108) | P < 0.001 | |
| Death · mean follow-up 70.64 ± 27.08 months | OR 7.57 (95% CI 1.97–53.9) | P = 0.004 | |
| 0.050.21520Ratio (log scale) |
- Major cardiovascular events (MACE) — Patients with MACE (overall)
- 19
- Death — Deaths from any cause (overall)
- 13
Predictors of subclinical atherosclerosis
- Significant predictors on multivariate analysis: male sex, diabetic nephropathy, tobacco exposure, higher HbA1c, older age, longer diabetes duration
Original publication
Unseen threat: how subclinical atherosclerosis increases mortality risk in patients with type 1 diabetes. Cardiovasc Diabetol. Published 17 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →